Search Results
Search this site
191 results found
- Is Your “Microbiome-Friendly” Seal Worth the Paper It’s Printed On?
“Microbiome-friendly” has become one of skincare's most attractive claims. It suggests science, gentleness, and a product that understands modern skin research. Yet there is an uncomfortable question: what does the seal prove? Where did “microbiome-friendly” certification come from? Most microbiome certifications were developed by private organisations rather than regulators. The best known was launched in 2018 by MyMicrobiome, a German start-up founded around Dr Kristin Neumann. Their purpose is valuable: a standardised way of assessing whether a formulation is unlikely to damage selected skin microorganisms in the laboratory; however, these measures are only part of the picture. What does it test and what does it not test? Certification assesses whether a product is unlikely to disrupt selected skin microorganisms under controlled laboratory conditions. Testing may examine whether the formulation: Preserves beneficial microbes Avoids promoting harmful species Maintains microbial diversity within a defined panel Meets microbiological quality standards It does not typically assess: How the microbiome responds during real-world use Whether microbial changes translate into clinical skin benefits How age, skin type, ethnicity, health and environment influence those responses Why are regulators pushing back on seal-only substantiation? Regulators are raising expectations for how microbiome claims are substantiated. They expect evidence matching the consumer’s interpretation. “Tested to preserve microbial balance” is very different from “restores your skin microbiome”. The stronger the implied benefit, the stronger the evidence required. What does a regulator-defensible microbiome claim look like in 2026? The strongest claim combines multiple layers of evidence: laboratory studies, human microbiome sequencing where appropriate, clinical skin measurements and transparent documentation. Together, these form a weight-of-evidence approach far more robust under scrutiny. Is the seal still worth having? Absolutely. The seal remains a useful signal that a product has undergone independent laboratory assessment, and it builds consumer confidence. The mistake is treating the seal as the destination rather than the starting point. It should sit alongside a broader evidence package, not replace it. What would you put on a claim file if you were audited tomorrow? A defensible claim file links the marketing claim to the evidence behind it: exact claim wording, product details, scientific rationale, testing methods and results, microbiome data, clinical outcomes, safety assessments, and documentation showing the evidence supports the consumer message. The strongest brands will not abandon the seal, but make sure the evidence behind it is stronger than the badge in front of it.
- Peptide Complexes: Unlocking the Power of Skin Signalling
Peptide complexes are blends of short chains of amino acids designed to interact with the skin. Found in serums, creams and treatments, they are often positioned as “active” ingredients targeting firmness, wrinkles, pigmentation and repair. Unlike traditional ingredients that mainly hydrate or protect at the surface, peptides work by influencing how skin behaves. They help guide key processes within the skin, offering a more targeted and considered approach to skincare. What we know Peptides are short amino acid chains that can mimic fragments of natural skin proteins, triggering biological responses linked to repair and regeneration 1. Different peptide types perform distinct roles. Signal peptides stimulate collagen and elastin production, carrier peptides deliver trace elements such as copper, and neurotransmitter-inhibiting peptides can soften expression lines 1, 2. Peptides also influence inflammation, pigmentation and barrier function, linking them to a wide range of skin concerns beyond ageing 3, 4. When combined into complexes, peptides can act across multiple pathways, supporting more comprehensive and targeted skin responses 1, 2, 3. Industry impact and potential Peptide complexes are shifting skincare towards more targeted, mechanism-led innovation: Mechanism-driven design: Building peptide combinations around defined biological pathways rather than marketing-led blends. From single actives to systems: Using complementary peptides to influence multiple processes, from collagen synthesis to inflammation. Advanced delivery strategies: Improving stability and penetration to ensure peptides reach viable skin layers. Our position At Sequential, we provide insight into how peptide complexes shape skin biology by integrating peptide research with multi-omic and microbiome analysis, supporting the development of formulations designed for real-world impact. Using our global database of 50,000+ samples, we help brands see how peptide-based products work in the skin, supporting the development of formulations that lead to real, long-term skin health improvements. References Pintea, A, et al. (2025). Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review. Biomolecules, 15, (1), 88. Ngoc, L, et al. (2023). Insights into Bioactive Peptides in Cosmetics. Cosmetics, 10, (4), 111. Mao, Z. (2025). Frontiers in Skin Rejuvenation: Recent Advances in Anti-Aging Skincare Technologies Based on Proteins, Peptides, and Peptide Derivatives. Modern Health Science, 8 (1), 69. Zhao, X, et al. (2021). Collagen peptides and the related synthetic peptides: A review on improving skin health. Journal of Functional Foods, 86, 104680.
- Sebum Metabolomics: Beyond Oil, Towards Insight
Sebum metabolomics is the study of the small molecules and lipids present in sebum, the oily substance produced by the skin. While often associated only with oiliness or acne, sebum is a biologically active mixture that reflects what is happening within the skin. By analysing sebum, it is possible to capture a chemical snapshot of skin function. This offers a non-invasive way to understand processes such as inflammation, barrier changes and microbiome activity, as well as how skin responds to environmental factors and skincare products. What we know Sebum is composed of triglycerides, free fatty acids, wax esters, squalene and cholesterol, playing a key role in barrier function, antimicrobial defence and protection against environmental stressors 1. Metabolomic analysis can map hundreds of molecules within sebum, providing a detailed profile of skin biology using simple, non-invasive sampling methods 2. Sebum reflects both internal processes and external exposures, linking it to inflammation, microbiome activity, hormonal changes and environmental impact 3. Distinct sebum profiles have been linked to conditions such as acne, sensitivity and barrier dysfunction, supporting its role as a biomarker of skin health 1, 3. Industry impact and potential Sebum metabolomics is enabling a shift towards more precise, data-driven skincare: Skin profiling and diagnostics: Using sebum as a non-invasive readout to better classify skin states and risks. Product evaluation: Measuring how formulations change skin at a molecular level, beyond visible effects. Targeted formulation design: Developing products that address underlying drivers such as lipid imbalance, inflammation and microbiome shifts. Our position At Sequential, our multi-omic approach captures metabolomic changes at the skin surface, providing insight into sebum composition and how it responds to products in real-world conditions. By capturing how formulations influence sebum composition, we help brands develop targeted, evidence-led skincare grounded in measurable change. Using our global database of 50,000+ samples, we support the development of formulations that respond to individual skin needs, moving beyond surface-level effects towards more precise, long-term skin health outcomes. References Géhin, C., Tokarska, J., Fowler, S., Barran, P., & Trivedi, D. (2023). No skin off your back: the sampling and extraction of sebum for metabolomics. Metabolomics, 19. https://doi.org/10.1007/s11306-023-01982-3. Zhang, J., Wu, F., Wang, J., Qin, Y., & Pan, Y. (2024). Unveiling the Metabolomic Profile of Oily Sensitive Skin: A Non-Invasive Approach. International Journal of Molecular Sciences, 25. https://doi.org/10.3390/ijms252011033. Isom, M., & Desaire, H. (2024). Skin Surface Sebum Analysis by ESI-MS. Biomolecules, 14. https://doi.org/10.3390/biom14070790.
- Keratosis Pilaris: More Than Just Rough Skin
Keratosis pilaris (KP) is one of the most common yet misunderstood skin conditions. Often presenting as rough texture on areas like the arms, thighs or buttocks, it is medically harmless and can be frustrating to live with. Frequently dismissed as dry skin and treated with simple moisturisers or harsh exfoliation, it can persist despite consistent care. For many people, this can lead to a cycle of over-treating the skin, increasing irritation without addressing the underlying texture. As awareness of skin comfort and barrier-friendly care grows, there is increasing recognition that KP requires gentle, sustained support rather than quick or aggressive fixes. What we know KP is a disorder where keratin builds up and blocks hair follicles, sometimes trapping hairs and causing rough, bumpy skin appearance 1. KP is linked to abnormalities in the pilosebaceous unit which is the hair follicle's structural unit, comprised of the hair follicle and its associated sebaceous gland and arrector pili muscle 2. KP commonly begins in childhood or adolescence and can affect up to 50–80% of adolescents and ~40% of adults, with notable impacts on skin confidence and quality of life 3. Industry impact and potential KP presents a clear opportunity for skincare innovation beyond basic moisturisation and exfoliation: Barrier-first formulations: Products that support barrier repair alongside gentle keratolysis to improve texture without irritation. Smarter exfoliation systems: Balanced use of acids, urea and moisturising ingredients to smooth skin without causing irritation over time. Combination approaches: Using exfoliation, hydration and follicle-focused care rather than relying on single solutions. Education-led care: Setting realistic expectations, as KP often requires sustained, consistent management rather than quick fixes. Our position At Sequential, we help brands look beyond surface smoothing claims and understand how their products actually affect the skin barrier and hair follicles in real-world use. By combining microbiome profiling with molecular, metabolomic and multi-omic analysis, we can assess how products influence skin texture, keratin build-up and skin barrier resilience over time. Using our global database of 50,000+ samples, we can support the development of evidence-led formulations that target the biological drivers of KP rather than short-term cosmetic appearance alone. References Hwang, S. et al. (2008). Keratosis pilaris: a common follicular hyperkeratosis. Cutis, 82, 177–180. Reddy, S. et al. (2021). Role of acids, steroids and kinase inhibitors in keratosis pilaris. Cureus, 13, e18917. Wang, J. et al. (2018). Keratosis pilaris and therapeutic options. Am J Clin Dermatol, 19, 733–757.
- The Perimenopausal Shift in Skin and Scalp Biology
Perimenopause brings profound, hormone-driven changes to skin and scalp biology, yet these shifts are still dismissed as “ageing.” For many people, the experience is sudden and unsettling: skin that once felt predictable becomes dry or reactive; hair begins to thin, shed or change texture; the scalp becomes itchy or persistently irritated. These changes can arrive quickly, without warning or clear guidance on what is happening or why. As conversations around menopause become more open, there is growing recognition that perimenopausal skin and scalp need different support. These are not cosmetic inconveniences but biological transitions shaped by fluctuating hormones and individual physiology. Understanding what changes during this phase is essential for developing products that respond to underlying biology, not just visible symptoms. What we know Falling and fluctuating oestrogen levels, alongside a relative rise in androgens, alter collagen production, barrier integrity and sebum regulation, contributing to dryness, sensitivity and reduced elasticity ¹. Hair follicles are oestrogen-responsive; reduced oestrogen shortens the growth phase, leading to increased shedding, finer hair and slower regrowth, often most visible at the temples and crown ². Hormonal shifts combined with scalp skin ageing (reduced collagen, vascularity and barrier function) increase susceptibility to irritation, inflammation and microbiome imbalance, contributing to thinning and discomfort ³. Around 60–70% of women report skin changes and up to 80% report hair symptoms during perimenopause, with wide variation in timing and severity, making one-size-fits-all solutions ineffective ¹. Industry impact and potential Perimenopause opens new opportunities for targeted innovation: Life-stage specific care: Products designed around hormonal transitions rather than chronological age. Scalp-first approaches: Supporting barrier health and follicle environments alongside hair fibres. Long-term support: Moving beyond quick fixes to sustained skin and scalp resilience. Broader hormone insight: Expanding research beyond oestrogen to include hormones such as progesterone. Our position At Sequential, we help brands understand how perimenopausal skin and scalp respond under real-world conditions. By combining microbiome profiling with molecular, metabolomic and multi-omic analysis, we can track changes in barrier function, inflammation and follicle-relevant pathways over time. Using our global database of 50,000+ samples, we can benchmark responses across life stages to support products that genuinely meet perimenopausal needs. References Zouboulis, C. et al. (2022). Skin, hair and beyond: the impact of menopause. Climacteric, 25, 434–442. Kamp, E. et al. (2022). Menopause and hair disorders. Clin Exp Dermatol, 47, 2110–2116. Williams, R. et al. (2020). Hair ageing and the follicle environment. Exp Dermatol, 29, 588–597.
- In Vitro Cosmetic Testing Is Quietly Dying
A positive result in a cell culture dish once supported many cosmetic claims: a collagen marker increased, or an inflammatory pathway decreased. But consumers buy products for what happens on their skin. As claims become more ambitious, evidence standards are shifting. In vitro remains valuable, but relying on it as the entire proof story is increasingly outdated. Why are in vitro skin models losing credibility? Regulators and consumers are asking a harder question: “Does this model predict what happens in real human skin?” In vitro systems offer valuable biological insight, but they simplify a complex organ. Skin is an ecosystem of immune signalling, vascular influence, environmental exposure and microbes. What can in vitro never fully capture? Skin responses vary between individuals due to age, genetics, hormones, lifestyle and microbiome differences. The microbiome is especially complex, involving microbial interactions, immunity, metabolites and barrier function. Simplified models can provide valuable insights, but they cannot fully predict real-world skin responses. Where does in vitro still earn its place and where does it become a trap? In vitro remains a powerful tool in cosmetic science when used for the right questions. It is valuable for: · Screening ingredients · Supporting safety assessment · Comparing formulations The risk is turning a biological signal into a consumer promise. A fibroblast producing more collagen does not prove fewer wrinkles, and a growth assay does not prove improved microbiome health. The mistake is not using in vitro; it is asking it to prove more than it can. What does in vivo multi-omics actually look like? Multi-omics sounds complex, but the principle is simple: measure multiple biological layers together. A study may combine microbiome sequencing, metabolomics, transcriptomics and clinical measurements such as hydration, redness or barrier function. Instead of asking “did one marker change?”, we can ask: • Did the product alter microbial communities? • Did those changes influence biological pathways? • Did skin function improve? • Did consumers experience a measurable benefit? This moves cosmetic testing from isolated signals towards a systems-level understanding of skin. Will regulators ban in vitro-only substantiation? Probably not. The bigger shift is the rising expectation for evidence quality. Regulators are increasingly focused on whether evidence matches the claim. Validated in vitro methods remain appropriate for safety and mechanistic questions, but claims involving complex outcomes such as inflammation or visible ageing require evidence that reflects real-world effects. How fast should brands move? Strategically, not universally. Routine safety testing and early screening still have a place, but flagship products built on complex biological claims must move to a relevant human evidence base. In vitro is for understanding. Human studies for proving. Multi-omics for explaining. The strongest brands will not abandon laboratory models. They will use them within a fuller evidence ecosystem.
- Vaginal Multiomics: Understanding the System, Not the Signal
The vaginal ecosystem is not just a microbial community. It is a host-microbe system shaped by hormones, immunity, metabolites, and local chemistry. Multiomics, a combination of microbiome, metabolome, immune signals, and genomics, moves the field beyond "which bacteria are present?" to what they are doing, how the host responds, and what that means for health. What we know This approach has transformed understanding of the vaginal ecosystem, revealing complex host–microbe interactions, functional diversity, and links to BV, reproductive outcomes, and gynaecological cancers 1. The mix of small molecules in the vagina (metabolites) is one of the best ways to understand its state. Certain fats (lipids) help show levels of inflammation, while amino-acid by-products reflect which bacteria are present and the pH 2. The vaginal environment is different for everyone and changes over time. Simple “normal” vs “abnormal” labels miss important differences between people 3. Recent advances include AI-powered diagnostic models that integrate microbiome and metabolome data for improved BV detection 4. Impact and potential Vaginal multiomics opens real innovation pathways. Microbiome-compatible formulation: Designing intimate care that avoids disrupting the vaginal microbiome Prebiotic and postbiotic development: Targeting favourable metabolic environments, not simply eliminating bacteria. Longitudinal testing and claims: Shift from single timepoint testing to tracking changes over time (e.g. across cycles, treatment use), enabling more meaningful and defensible claims. Subtype-driven product design: Move beyond one-size-fits-all “intimate care” by developing products tailored to different dysbiosis or symptom subtypes identified through multiomics. Our position At Sequential, we approach the skin as an ecosystem, not a single pathway. Our focus is on generating measurable, real-world evidence of how formulations interact with both the barrier and the microbiome simultaneously. Using integrated multi-omics approaches, we can quantify changes in lipid composition, protein expression, microbial activity, and overall skin resilience over time. By testing formulations on diverse skin types and environments, using our global sample database, we generate insights that reflect real-world use rather than idealised conditions. References 1. Ottinger, S., et al. (2024). The human vaginal microbiota. Curr Opin Microbiol, 77, 102422. 2. Bokulich, N., et al. (2022). Multi-omics integration in the cervicovaginal microenvironment. PLoS Comput Biol, 18, e1009876. 3. Challa, A., et al. (2024). Multi-omics biomarkers of bacterial vaginosis. J Eur Acad Dermatol Venereol, 38, 1152–1165. 4. Saluzzo, S., et al. (2024). AI-powered multiomics in bacterial vaginosis. J Eur Acad Dermatol Venereol, 38,999 -1000.
- Your Skin Barrier Isn't Working Alone
The skin barrier is often described as a wall. In reality, it’s more like a living ecosystem. At its surface sits the skin microbiome, a complex community of bacteria, fungi, and viruses that don’t just exist on the skin, but actively help it function. Rather than being passive, the microbiome works alongside the physical, chemical, and immune layers of the barrier to maintain resilience, regulate inflammation, and protect against environmental stress. When this relationship is balanced, skin performs optimally. When it’s disrupted, both barrier function and skin health can decline. What we know The microbiome acts as a co-regulator of skin function, working alongside the barrier and immune system 1. The microbiome is a diverse, site-specific ecosystem. Oily, moist, and dry areas host distinct communities 2,3. Commensal microbes actively support barrier integrity through effects on keratinocytes and lipid balance 1, 4. Dysbiosis, through reduced diversity, is associated with conditions such as acne, atopic dermatitis, and psoriasis, often alongside barrier disruption 1, 5. Industry impact and potential For formulation, this changes the goalposts. It’s no longer enough to protect the barrier or consider the microbiome in isolation. The focus should be on supporting the system as a whole. Barrier-first design: Prioritising formulations that maintain hydration, pH, and lipid balance to create conditions in which beneficial microbes thrive. Microbiome-compatible actives: Using prebiotics, postbiotics, and fermented ingredients where evidence supports functional benefit. Precision skincare: Leveraging microbiome profiling and multi-omic data to match products to different skin states, environments, and life stages. Our position At Sequential, we approach the skin as an ecosystem, not a single pathway. Our focus is on generating measurable, real-world evidence of how formulations interact with both the barrier and the microbiome simultaneously. Using integrated multi-omics approaches, we can quantify changes in lipid composition, protein expression, microbial activity, and overall skin resilience over time. By testing formulations on diverse skin types and environments, using our global sample database, we generate insights that reflect real-world use rather than idealised conditions. References Lee, H, et al. (2022). Skin Barrier Function and the Microbiome. Int J Mol Sci, 23. Smythe, P, et al. (2023). The Skin Microbiome: Current Landscape and Future Opportunities. Int J Mol Sci, 24. Prajapati, S, et al. (2025). Microbiome and Postbiotics in Skin Health. Biomedicines, 13. Harris-Tryon, T, et al. (2022). Microbiota and Maintenance of Skin Barrier Function. Science, 376, 940–945. Scharschmidt, T, et al. (2025). Skin Microbiome and Dermatologic Disorders. J Clin Invest, 135.
- Skin Doesn't Just Heal. It Rebuilds.
Skin repair is not simply about moisturising; it is a precisely coordinated biological response. From minor barrier disruption to full wound healing, the skin activates a sequence of processes to restore function, protect against further damage, and minimise long-term impact. In most cases, this process restores continuity, not perfection. Adult skin typically repairs with some level of structural compromise, making the balance between effective repair and excessive scarring a critical focus. What we know Skin repair is a multi-phase process involving inflammation, cell proliferation, extracellular matrix rebuilding, and remodelling 1. Most adult skin heals through repair (with scarring) rather than true regeneration of original structure 2. Barrier disruption increases TEWL, triggering keratinocyte activity, lipid synthesis, and inflammatory signalling 3. Effective repair is linked to restored hydration, improved lipid organisation, and reduced irritation risk 4. The balance between inflammation and regeneration is a key determinant of healing quality and outcomes 5. Industry impact and potential Skin repair is shifting skincare towards more targeted, biology-led formulation: Recovery first design: Designing products that prioritise reducing TEWL, preserving lipid organisation and minimising unnecessary irritation, before cosmetic goals. Phase-specific formulations: Moving beyond one-size-fits-all "repair" to products built for distinct needs Inflammation control: Developing actives and combinations that calm the inflammatory cascade at the right time, reducing chronic low-grade inflammation that compromises repair and accelerates ageing. Next-generation delivery systems: Drawing on advances in wound care, creating vehicles that actively maintain a stable repair environment rather than just carrying actives. Our position At Sequential, we support brands in moving from broad “skin repair” claims to clearly defined, evidence-based outcomes. Our approach combines in vivo testing with molecular-level analysis to understand how formulations influence key aspects of repair, including barrier recovery, inflammation, and skin resilience. Drawing on a global database of 50,000+ biological samples, we provide insights across diverse skin types, conditions, and environments, supporting the development and substantiation of repair-focused formulations with greater clarity, confidence, and scientific grounding. References 1. Sorg, H, et al. (2016). Skin Wound Healing: An Update on Current Knowledge and Concepts. Eur Surg Res, 58, 81–94. 2. Peña, O, et al. (2024). Cellular and Molecular Mechanisms of Skin Wound Healing. Nat Rev Mol Cell Biol, 25, 599–616. 3. Tottoli, E, et al. (2020). Skin Wound Healing Process and Emerging Technologies. Pharmaceutics, 12. 4. Lee, H, et al. (2022). Skin Barrier Function and the Microbiome. Int J Mol Sci, 23. 5. Atallah, C, et al. (2025). Bioengineered Skin Microbiome in Cosmetics. Cosmetics, 12.
- Ectoin Is Redefining Barrier Care
Ectoin is a naturally occurring small molecule produced by bacteria that survive extreme conditions: heat, dryness, and high salt. In skincare, it does something similar: it wraps a layer of organised water around skin cells and proteins, helping them stay stable under stress. This reduces transepidermal water loss (TEWL) and helps skin resist environmental stress from the inside out. This makes it a different kind of barrier ingredient, one that stabilises rather than simply shields. What we know Ectoin works by forming a protective water layer around cell membranes, which helps stabilise the skin barrier rather than simply sitting on top of it1. In clinical studies, 5.5–7% ectoin formulations improved dryness, itch, and dermatitis scores in atopic and retinoid-stressed skin, with a strong safety record2. Topical ectoin reduces TEWL and inflammatory cytokines, with effects demonstrated in both healthy and barrier-compromised skin3. Ectoin is generally well tolerated, with only mild, transient sensations reported in some cases; however, current evidence is limited, with many studies small or short, meaning more rigorous trials are needed4. Industry impact and potential Ectoin presents an opportunity to move it beyond "gentle hydration" into barrier-performance science with measurable endpoints: Barrier-first formulation: Combining ectoin with ceramides and humectants in leave-on systems designed for sensitive, over-exfoliated, or retinoid-stressed skin. Stress and recovery positioning: Testing ectoin under realistic conditions such as being exposed to pollution, cold-weather stress, and post-procedure skin to generate evidence where barrier resilience is the primary claim of a formulation. Clinical design upgrade: Investing in randomised, longer-duration trials with objective endpoints such as TEWL, hydration, and redness imaging to build a defensible evidence base. Platform thinking: Using ectoin as part of a broader barrier-health story, not as a solo hero ingredient that has to carry the whole product. Our position At Sequential, we see ectoin as both a formulation and an evidence opportunity. Through our end-to-end clinical testing platform, we support brands from study design to data interpretation and combine in vivo microbiome and biophysical testing, targeted biomarker analysis, and real-world study conditions to generate meaningful and relevant data. By leveraging our 50,000+ database of samples and formulation insights, we can help translate ectoin’s mechanism into measurable outcomes. References 1. Bujak, T., et al. (2020). Ectoine–surfactant complexes in cleansing cosmetics. Molecules, 25, 1433. 2. Kauth, M., et al. (2022). Topical ectoine for inflammatory skin diseases: a systematic review. Dermatol Ther, 12, 295–313. 3. Załęska, I., et al. (2025). Ectoine effects on CO₂ laser-damaged skin. Molecules, 30, 2470. 4. Graf, R., et al. (2008). Ectoine as a natural cell protectant. Clin Dermatol, 26, 326–333.
- Why Male Pattern Baldness Is More Than Just Hair Loss
Male pattern baldness, also known as androgenetic alopecia, is the most common form of hair loss in men. Despite this, it is often dismissed as a cosmetic inconvenience or ageing. For many, hair loss is neither trivial nor purely aesthetic; it can affect identity, confidence and psychological wellbeing. Growing interest in scalp health and hair retention has increased demand for approaches that go beyond concealment. This has caused a shift to focus on understanding why hair loss occurs, why it progresses differently between individuals, and what supports hair retention over time. Addressing male pattern baldness responsibly means moving past surface-level claims and toward solutions informed by biology and long-term outcomes. What we know Male pattern baldness is a progressive condition in which genetically susceptible hair follicles gradually shrink, producing finer, shorter hairs before visible growth stops, even though follicles often remain biologically active 1. Sensitivity to dihydrotestosterone (DHT), rather than hormone levels alone, drives changes in hair growth cycles and determines where and when hair loss occurs 2. Inflammation, oxidative stress and impaired scalp barrier function accelerate follicle miniaturisation and thinning 3. Scalp microbiome composition and sebum dynamics influence inflammatory responses and follicle health 4. Industry impact and potential A deeper biological understanding opens new directions for hair and scalp innovation: Targeted scalp support: Products that improve scalp barrier function and follicle environment rather than masking hair loss. Combination strategies: Addressing inflammation, scalp health and hormonal pathways together. Complementary care: Shampoos and leave-ons that reduce breakage, calm the scalp and support continued use of treatments like minoxidil. Future innovation: Increasing interest in non-hormonal approaches and why certain scalp regions are more susceptible to hair loss. Our position At Sequential, we help brands understand what hair and scalp formulations are doing in real-world conditions. By combining microbiome profiling with molecular, metabolomic and multi-omic analysis, we track changes in scalp health, inflammatory activity and follicle-relevant pathways over time. Drawing on our global database of 50,000+ biological samples, we benchmark formulations across different scalp types and environments, supporting the development of products that promote long-term hair and scalp health. References Redmond, L. et al. (2023). Male pattern hair loss and developmental origins. Exp Dermatol, 32, 1174–1181. Xiao, Y. et al. (2025). Immune and non-immune interactions in androgenetic alopecia. Clin Rev Allergy Immunol, 68. Du, F. et al. (2024). Oxidative stress in hair follicle development. J Cell Mol Med, 28. Polak-Witka, K. et al. (2019). The role of the scalp microbiome in hair follicle biology. Exp Dermatol, 29, 286–294.
- Skincare Preservation: Balancing Safety and the Skin Microbiome
Preservation is essential in skincare, ensuring products remain safe and stable throughout use. Without it, water-based formulations are vulnerable to contamination, posing risks to both product performance and consumer health. At the same time, growing awareness of the skin microbiome has raised questions about how preservatives interact with the skin’s natural ecosystem. This has shifted the conversation from simply preserving products to understanding how preservation systems work alongside skin biology. What we know Preservatives prevent the growth of bacteria, yeast and mould in cosmetic products, particularly those containing water, making them essential for product safety and shelf life 1. The skin microbiome is a complex ecosystem that supports barrier function, immune balance and repair processes. In laboratory studies, some preservatives can inhibit both harmful and beneficial skin bacteria, potentially causing microbiome disruption 2. However, human studies using real-world formulations typically show little to no lasting change in microbiome diversity or abundance when products are used as directed 3. Industry impact and potential Preservation is driving a shift towards more considered, biology-led formulation: Barrier-first formulations: Pairing panthenol with other ingredients such as ceramides and fatty acids to support barrier resilience. Microbiome-aware preservation: Designing systems that protect the product while minimising disruption to the skin ecosystem. From safety to balance: Moving beyond antimicrobial strength alone to consider how full formulations interact with skin over time. Alternative preservation strategies: Exploring multifunctional ingredients and formulation approaches that reduce reliance on traditional preservatives. Our position At Sequential, we help brands move beyond single-ingredient thinking by evaluating how preservation systems function within the full formulation. Using microbiome and multi-omic analysis, we generate real-world insight into how products interact with the skin ecosystem. Supported by our global database of 50,000+ samples, we enable the design of preservation strategies that are both effective and aligned with skin biology. References Halla, N. et al. (2018) Cosmetics preservation: A review on present strategies. Molecules, 23( 7): 1571. Pinto, D. et al. (2021) Effect of commonly used cosmetic preservatives on skin resident microflora dynamics. Scientific Reports, 11: 8695. Callejon, S. et al. (2023) Impact of leave-on skin care products on the preservation of skin microbiome. Clinical, Cosmetic and Investigational Dermatology, 16: 2727.











